{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hyperhidrosis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"5d7852f4-9b06-5320-86de-ee56104314fc","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 0f2aad10-40fc-46f5-9571-39cebad316e7 --><h2>Changes</h2><!-- end field 0f2aad10-40fc-46f5-9571-39cebad316e7 -->","summary":null,"htmlStringContent":"<!-- begin item 84f3cad5-2b13-4a44-8181-5a7af5ce9b1d --><!-- begin field f30be772-045c-4d38-96a4-84f91d3a4601 --><p><strong>May 2018 </strong>— reviewed. A literature search was conducted in May 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. The Background information section has been expanded in line with current CKS style. The management recommendations have been updated in line with the current literature.</p><!-- end field f30be772-045c-4d38-96a4-84f91d3a4601 --><!-- end item 84f3cad5-2b13-4a44-8181-5a7af5ce9b1d -->","topic":{"id":"d2b54f08-d9cb-5147-a5aa-27e00b5cfd82","topicId":"9dacba69-b1b5-408f-a26d-a8e884033a25","topicName":"Hyperhidrosis","slug":"hyperhidrosis","lastRevised":"Last revised in May 2018","chapters":[{"id":"51b68ff2-e22f-5146-98b1-ed247449fada","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d247fa3c-c9d7-571f-9348-9d3a5b9a827f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"3db15061-64ce-5067-8778-049202743014","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5d7852f4-9b06-5320-86de-ee56104314fc","slug":"changes","fullItemName":"Changes"},{"id":"37a4f575-9e64-5591-9459-613a50da6a5b","slug":"update","fullItemName":"Update"}]},{"id":"6608a015-2abe-5be8-882a-844689719b29","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"2b31616d-6688-52e8-abfe-1c1e9567773c","slug":"goals","fullItemName":"Goals"},{"id":"164bcdd9-2d27-5afc-8857-f691d732e91a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f04b5274-abcd-5e07-9d0e-218d1b25b64a","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"35e097f0-6a28-54ce-91f0-09584dff79fd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0c245ac4-9908-5ec7-9443-c8d80afba273","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"479a66f8-4820-5838-babb-6b95327bf868","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e78f871f-1030-583b-b3a3-fd5932d63577","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f573ecee-b6e5-56a9-b610-ad80005d58b7","slug":"definition","fullItemName":"Definition"},{"id":"5105b210-71a6-505f-9fe7-96123ea1beba","slug":"causes","fullItemName":"Causes"},{"id":"3064f161-ea2d-5e49-9dbb-092faa5d5f71","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2e2ec09e-2d90-5f72-b368-813dea5aee6e","slug":"complications","fullItemName":"Complications"},{"id":"8132bf09-7bc9-55ce-8d34-d18405a2c171","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"13f16bec-4872-59e8-9996-2d88a053d081","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dfa50ec8-3fda-51b5-9903-61e58cc06753","slug":"assessment","fullItemName":"Assessment"}]},{"id":"45eb7b55-769c-50ef-9ce2-44c27469518c","fullItemName":"Management","slug":"management","subChapters":[{"id":"e0426c02-494d-544f-ac4b-5a344571652a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"f83d14e6-24e3-513f-8d39-8b68803222b0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"00e65205-feb9-59d3-8035-446868d1caab","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7466396-123d-5050-8dd8-88ec7ce286f7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0574994c-afef-578e-ab8a-e3d78c0757e3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"68b43c06-7da3-5e66-ae57-bc294e301587","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"67e38cee-224f-54bd-ad61-431d5cc9c006","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"373675d4-86fc-5734-962f-d2aad8d56169","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"26f4cbb7-dfc9-5c02-9786-950141a26758","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3db15061-64ce-5067-8778-049202743014","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c02f2b59-938f-5b2d-afd9-0758f566582f","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d63f1e85-6a54-47f4-8182-e844c2ae7334 --><h3>Previous changes</h3><!-- end field d63f1e85-6a54-47f4-8182-e844c2ae7334 -->","summary":null,"htmlStringContent":"<!-- begin item 62aa8af6-be34-492c-abc2-a0ea1640005c --><!-- begin field 2412f43a-876a-4af3-bf94-54c19739e8fc --><p><strong>July 2013 </strong>— reviewed. A literature search was conducted in May 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. No major changes to the recommendations have been made.</p><p><strong>October 2010 </strong>— minor update. Text amended to reflect that aluminium chloride 20% spray is prescribable, but not a licensed medicinal product. Issued in October 2010.</p><p><strong>November 2008 to March 2009 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Four important new documents have been published since the previous CKS guidance was released: An evidence-based review, <em>Treatments for excessive armpit sweating; A Canadian expert consensus statement, <em>A comprehensive approach to the recognition, diagnosis and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee; Web-based guidelines from the International Hyperhidrosis Society on the diagnosis and management of primary focal, and generalized, hyperhidrosis; A large, randomized, placebo-controlled trial of botulinum toxin type A in the treatment of primary axillary hyperhidrosis.</em></em> There are no major changes to the recommendations.</p><p><strong>January 2006 </strong>— minor update to the text in the section on <em>Iontophoresis</em>. Issued in February 2006.</p><p><strong>May 2005 </strong>— written. Validated in September 2005 and issued in November 2005.</p><!-- end field 2412f43a-876a-4af3-bf94-54c19739e8fc --><!-- end item 62aa8af6-be34-492c-abc2-a0ea1640005c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}